Home / Companies / Akero Therapeutics, Inc. / 2 Dec 2025
Akero Therapeutics, Inc.: meeting of 2 Dec 2025
Votes reported on Form N-PX, item by item
370 Form N-PX filers reported votes at the Akero Therapeutics, Inc. meeting of 2 Dec 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
6 vote records from 4 filers. 1 of the 3 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on pay tied to a merger or sale
537 vote records from 366 filers. 34 of the 338 filers that marked the item either way voted against management. 28 filers reported this item without a management mark.
EXTRAORDINARY TRANSACTIONSIssuer
EXTRAORDINARY TRANSACTIONS: management items
Management items in this category are shown together; filers word and number them differently.
189 vote records from 95 filers. 0 of the 94 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
243 vote records from 112 filers. 8 of the 112 filers that marked the item either way voted against management.
How the largest families voted
| Family | 2. Merger pay |
|---|---|
| Vanguard | For |
| BlackRock and iShares | For |
| Fidelity | For |
| Dimensional | For |
| State Street and SPDR | For |
| American Century | For |
| Franklin Templeton | For |
| Invesco | For |
| Equitable | For |
| Charles Schwab | For |
| Nuveen and TIAA | Against * |
| ProShares and ProFunds | For |
| John Hancock and Manulife | For |
| Morgan Stanley, Eaton Vance and Calvert | For |
| J.P. Morgan | Against * |
| Goldman Sachs | For |
| PGIM and Prudential | For |
| Jackson National funds | For |
| Northern Trust and FlexShares | Against * |
| SEI | For |
| T. Rowe Price | For |
| Lincoln Financial | For |
| Voya | Against * |
| First Trust | For |
| Russell Investments | For |
| Nationwide | For |
| Victory Capital | For |
| Brighthouse Funds | For |
| Guggenheim and Rydex | For |
| Columbia Threadneedle | For |
| BNY Mellon | For |
| Principal | For |
| Pacific Life funds | For |
| Global X | For |
| AllianceBernstein | Against * |
| Hartford Funds | For |
| DWS | For |
| Allspring | For |
| MassMutual | For |
| Macquarie and Delaware Funds | For |
| Janus Henderson | For |
| Neuberger Berman | For |
| Natixis and Loomis Sayles | For |
| Baird | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Akero Therapeutics, Inc. meeting?
370 Form N-PX filers reported votes at the meeting of 2 Dec 2025. On say-on-pay, 1 of 3 voted against management (33.3%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Akero Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Akero Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Akero Therapeutics, Inc. with a meeting date within three days of 2 Dec 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.